Development of novel small molecule antiviral therapeutics for pathogens with epidemic potential

Apie kvietimą

Expected Outcome: This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination “Tackling diseases and reducing disease burden”. To that end, proposals under this topic should aim to deliver results that are directed at, tailored towards and contributing to all the following expected outcomes: The scientific and clinical communities have a better understanding of and access to experimental antivirals for the prevention and treatment of emerging or re-emerging viral infections, as well as for further clinical investigation. Candidate antiviral therapies are available to treat patients for emerging and re-emerging viral infections, increasing therapeutic options for clinical deployment in case of an epidemic or pandemic. Scope: Infectious diseases remain a major threat to health and health security in the EU and globally. Viral disease emergence is already being accelerated by climate change, and thus a proactive approach to the development of antiviral prophylactics and therapeutics in preparedness for future infectious disease outbreaks is needed. The availability of antivirals targeting conserved viral or host mechanisms would provide a critical preparedness measure against future health threats caused by (re)emerging infectious disease epidemics or pandemics, due to infectious disease epidemics or pandemics. This topic contributes to strengthening the Research and Innovation ecosystem within the EU and supports the implementation of the European Medical Countermeasures Strategy[1]. Antibodies and antibody derived proteins are excluded from the scope of this topic. Applicants should explicitly state in their proposal which of the following viruses/groups of viruses is targeted and the proposed work should address only this specific virus/group of viruses. The proposed work should aim to advance the development of novel or existing antiviral candidates targeting exclusively one of the following viruses/groups of viruses: Junin mammarenavirus and/or Lassa mammarenavirus Tick-borne encephalitis virus and/or Japanese encephalitis virus Andes virus and/or Hantaan virus and/or Sin Nombre virus Hendra virus Enterovirus D68 Venezuelan equine encephalitis virus Identifying a specific virus/group of viruses does not preclude the exploration of these antiviral candidates' effects on other viruses/groups of viruses. Proposals should thus aim to diversify and accelerate the global prophylactic and therapeutic research and development portfolio for emerging and re-emerging viral infections, and to strengthen the leading role of the EU in prophylactic and therapeutic research and development. Proposals should address some of the following research areas: Discovery and selection of candidate antivirals with consideration for intra-family and/or variant-transcending potential. Optimisation of selected candidates to improve potency, selectivity, pharmacokinetics, and developability, using…